For the year ending 2025-12-31, GANX had $10,456,366 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -20,161,099 |
| Depreciation and amortization | 94,046 |
| Stock-based compensation expense | 1,803,195 |
| Other non-cash items | -804,938 |
| Prepaid expenses and other current assets | 82,119 |
| Long term deposit and other noncurrent assets | -2,852 |
| Accounts payable and other current liabilities | -468,606 |
| Defined benefit pension plan | -130,568 |
| Deferred grant income | -328,071 |
| Total changes in operating assets and liabilities | 1,006,512 |
| Cash used in operating activities | -18,465,432 |
| Net proceeds from issuance of shares in 2024 atm program (note 14) | 18,059,379 |
| Net proceeds from issuance of shares in public offering (note 14) | 7,411,554 |
| Net proceeds from the exercise of warrants (note 14) | 3,218,552 |
| Net proceeds from the exercise of stock options (note 15) | 250,260 |
| Payments of offering costs (note 14) | 395,478 |
| Payments of current portion of long-term debt (note 12) | 96,501 |
| Cash provided by financing activities | 28,447,766 |
| Effect of exchange rate changes | 474,032 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 10,456,366 |
| Cash, cash equivalents and restricted cash at beginning of period | 10,417,558 |
| Cash, cash equivalents and restricted cash at end of period | 20,873,924 |
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)